Evaluation of Ga-DOTA-(D-Asp)$_n$ as bone imaging agents: D-aspartic acid peptides as carriers to bone

Kazuma Ogawa$^{1,2}$, Atsushi Ishizaki$^1$, Kenichiro Takai$^1$, Yoji Kitamura$^3$, Akira Makino$^4$, Takashi Kozaka$^4$, Yasushi Kiyono$^4$, Kazuhiro Shiba$^3$ & Akira Odani$^1$

$^{67}$Ga-DOTA-(L-Asp)$_{11}$ and $^{67}$Ga-DOTA-(L-Asp)$_{14}$, which have been developed as bone imaging agents, showed a high accumulation in bone and a rapid blood clearance in mice. However, peptides composed of D-amino acids are more stable in vivo than those composed of their L-equivalents. In this study, $^{67}$Ga-DOTA-(D-Asp)$_n$ ($n = 2, 5, 8, 11,$ or $14$) were synthesized using the Fmoc-based solid-phase methodology and evaluated. In hydroxyapatite binding assay, binding of $^{67}$Ga-DOTA-(D-Asp)$_n$ tended to increase with increasing length of the amino acid chain. $^{67}$Ga-DOTA-(D-Asp)$_{11}$ and $^{67}$Ga-DOTA-(D-Asp)$_{14}$ caused a high accumulation of radioactivity in the bones of the mice. However, the results for $^{67}$Ga-DOTA-(D-Asp)$_n$ and $^{67}$Ga-DOTA-(L-Asp)$_n$ were comparable. In urine analyses, the proportion of intact complex after injection of $^{67}$Ga-DOTA-(D-Asp)$_{14}$ was significantly higher than that of $^{67}$Ga-DOTA-(L-Asp)$_{14}$. Although $^{67}$Ga-DOTA-(D-Asp)$_{14}$ was more stable than $^{67}$Ga-DOTA-(L-Asp)$_{14}$, the properties of $^{67}$Ga-DOTA-(D-Asp)$_n$ and $^{67}$Ga-DOTA-(L-Asp)$_n$ as bone imaging agents may be comparable.

Recently, the performance of X-ray computed tomography (CT) and magnetic resonance imaging (MRI) method has been greatly improved, particularly in terms of their spatial resolution and technology for reconstructing the acquired images. Nuclear medicine imaging has been considered to be the most sensitive approach for diagnosing bone disorders such as bone metastases due to its ability to enable the early detection of abnormalities, namely, visualization of lesion sites before anatomical changes. For a long time, $^{99m}$Tc-methylene diphosphonate ($^{99m}$Tc-MDP) and $^{99m}$Tc-hydroxymethylene diphosphonate ($^{99m}$Tc-HMDP) have been widely used in bone imaging$^{1-5}$. Because $^{99m}$Tc has the convenient physical characteristics [moderate half-life (6.01 h) for clinical use, a generator-produced radionuclide, and appropriate gamma ray energy for imaging] and imaging methods using conventional gamma cameras are simple, $^{99m}$Tc-MDP and $^{99m}$Tc-HMDP are complexes of $^{99m}$Tc with bisphosphonate analogs having high affinity for bone since the phosphate groups in the bisphosphonate can be coordinated with calcium in hydroxyapatite crystals in bone.

The use of $[^{18}$F]$\text{NaF}$ for bone imaging was initially reported by Blau et al. in 1962$^6$ and approved by the US Food and Drug Administration in 1972. $[^{18}$F]$\text{NaF}$ accumulates at a high level in bone because of chemisorption and the exchange of fluoride anions with the hydroxyl groups in hydroxyapatite [Ca$_{10}$(PO$_4$)$_6$(OH)$_2$]. However, $[^{18}$F]$\text{NaF}$ had not been widely used due to its limited availability and high cost, but it has recently been reevaluated. The images obtained using clinical positron emission tomography (PET) generally have high spatial resolution and PET/CT scanners have become widely available commercially. Although Even-Sapir et al. reported that $[^{18}$F]$\text{NaF}$ PET imaging is significantly more sensitive than $^{99m}$Tc-MDP planar and $^{99m}$Tc-MDP single photon emission computed tomography (SPECT) imaging$^7$, the problems of limited availability and the high cost of cyclotrons have remained unresolved.

In recent years, $^{68}$Ga (T$_{1/2} = 68$ min) has drawn substantial attention as a positron emission radionuclide for clinical PET because of its attractive radiophysical properties, such as reasonable half-life for clinical use; it has particularly been used as a generator-produced radionuclide. $^{68}$Ga-PET does not require an on-site cyclotron because $^{68}$Ga can be eluted from the generator on demand. Moreover, as the parent nuclide, $^{68}$Ge (T$_{1/2} = 271$ days) has a long half-life, a generator could be used for a long period. Therefore, the demand for $^{68}$Ga-labeled compounds for the diagnosis of bone disorders, such as bone metastases, has increased. Some new

---

$^1$Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. $^2$Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan. $^3$Advanced Science Research Center, Kanazawa University, Kanazawa, Japan. $^4$Biomedical Imaging Research Center, University of Fukui, Eiheiji, Japan. Correspondence and requests for materials should be addressed to K.O. (email: kogawa@p.kanazawa-u.ac.jp)
radiogallium-labeled complexes for bone imaging have been developed in recent years8–14. Bisphosphonate analogs are used as carriers in these radiogallium-labeled complexes. For example, Fellner et al. reported that 68Ga-DOTA-conjugated bisphosphonate, 68Ga-BPAMD, showed high uptake in osteoblastic metastatic lesions in a first human PET study8. In addition, Suzuki et al. reported that 68Ga-NOTA-conjugated bisphosphonate, 68Ga-NOTA-BP, showed high bone affinity and rapid blood clearance in animal experiments9–11.

The acidic amino acid peptides (poly-glutamic and poly-aspartic acids) also have a high affinity for hydroxyapatite because side-chain carboxyl groups in the acidic amino acid peptides can be coordinated with calcium in hydroxyapatite, and could become carriers delivering drugs to bone16–18. Recently, 1,4,7,10-tetraazacyclododecan-1,4,7,10-tetraacetic acid (DOTA) has been used as a chelating site, and Ga-DOTA-conjugated acidic peptides [Ga-DOTA-(L-Asp)n], with varying peptide lengths (n = 2, 5, 8, 11, or 14), have been developed and evaluated using the easy-to-handle radioisotope 68Ga, which has a longer half-life (3.3 days), rather than 64Ga.6 Ga-DOTA-(L-Asp)11 and 68Ga-DOTA-(L-Asp)14 show high affinity for hydroxyapatite, high accumulation in bone, and rapid blood clearance in biodistribution experiments in normal mice. Accordingly, the bone/blood ratios of 68Ga-DOTA-(L-Asp)11, and 68Ga-DOTA-(L-Asp)14 are comparable to those of 99mTc-MDP and 68Ga-DOTA-Bn-SCN-HBP (Fig. 1A), a Ga-DOTA-conjugated bisphosphonate, which was developed and evaluated in our previous study11. In these Ga-DOTA-conjugated acidic amino acid peptide compounds, L-aspartic acid is used as the only component of the peptides. However, the peptides composed of D-amino acids could be more stable in vivo than the peptides built with L-amino acids because they are not readily recognized by the peptidases10. Thus, in this study, 68Ga-DOTA-(D-Asp)n (Fig. 1B) of varying peptide lengths (n = 2, 5, 8, 11, or 14) were synthesized and evaluated. Moreover, to compare the different acidic amino acids as components of the carrier, 68Ga-DOTA-(L-Glu)14 (Fig. 1C) and 68Ga-DOTA-(D-Glu)14 (Fig. 1D) were synthesized and evaluated in vitro and in vivo.

Results
Preparation of 68Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14. 68Ga-DOTA-(D-Asp)n, (n = 2, 5, 8, 11, or 14), 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14 were prepared by complexing DOTA-(D-Asp)n, DOTA-(L-Glu)14, and DOTA-(D-Glu)14 with 68Ga, respectively. Radiochemical yields of 68Ga-DOTA-(D-Asp)2, 68Ga-DOTA-(D-Asp)5, 68Ga-DOTA-(D-Asp)8, 68Ga-DOTA-(D-Asp)11, 68Ga-DOTA-(D-Asp)14, 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14 were 25%, 67%, 74%, 56%, 51%, 38%, and 68% respectively. After RP-HPLC purification, 68Ga-DOTA-(D-Asp)2, 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14 had radiochemical purities of over 95%. The formation of 68Ga-DOTA-(D-Asp)n, 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14 complexes were determined by examining the retention times in RP-HPLC analyses. The 68Ga-labeled complexes showed identical retention times as the corresponding nonradioactive complexes. The results indicated that the formation of 68Ga-labeled complexes were identical to those of nonradioactive Ga complexes, which were determined by MS.

Hydroxyapatite-binding assay. Figure 2 shows the percentage of each 68Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14 bound to hydroxyapatite beads. Binding of 68Ga-DOTA-(D-Asp)n to the beads increased with an increasing amount of hydroxyapatite, except for that of 68Ga-DOTA-(D-Asp)2. Binding of 68Ga-DOTA-(D-Asp)n to hydroxyapatite tended to increase with increasing length of amino acid chain. The binding affinities of 68Ga-DOTA-(L-Glu)14 and 68Ga-DOTA-(D-Glu)14 were comparable to that of 68Ga-DOTA-(D-Asp)14.

Biodistribution experiments. The biodistribution of 68Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14), 68Ga-DOTA-(L-Glu)14, 68Ga-DOTA-(D-Glu)14, and [18F]NaF, and 99mTc-MDP in normal mice is shown in Tables 1–9. Among these compounds, 68Ga-DOTA-(D-Asp)2, 68Ga-DOTA-(D-Asp)5, 68Ga-DOTA-(D-Asp)8, 68Ga-DOTA-(D-Asp)11, 68Ga-DOTA-(D-Asp)14, 68Ga-DOTA-(L-Glu)14, 68Ga-DOTA-(D-Glu)14, and [18F]NaF, and 99mTc-MDP showed high accumulation and retention of radioactivity in bone. 68Ga-DOTA-(D-Asp)2 showed moderate accumulation of radioactivity in bone; however, the level of radioactivity decreased 3 h after injection. 68Ga-DOTA-(D-Asp)2 caused subtle accumulation of radioactivity in bone. Although there was little radioactivity in other tissues at 3 h after the injection of 68Ga-DOTA-(D-Asp)14, 99mTc-MDP, and [18F]NaF because of rapid excretion via the kidneys, the radioactivity in the kidneys after the injection of 68Ga-DOTA-(L-Glu)14, and 68Ga-DOTA-(D-Glu)14 was retained.

Urine Analyses. The results of urine analysis using RP-HPLC after injection of 68Ga-DOTA-(L-Glu)14 and 68Ga-DOTA-(D-Asp)14 showed that a part of these complexes metabolized to more hydrophilic complexes; some radioactivity was eluted earlier than the intact complex. The ratio of the intact complex after injection of 68Ga-DOTA-(L-Glu)14 (85.8 ± 17.4%) was significantly higher than that of 68Ga-DOTA-(L-Asp)14 (55.0 ± 13.9%).

Discussion
It has been shown that the bisphosphonate structure is very useful as a carrier of physiologically active molecules or compounds with medicinal properties. This is particularly true for bone lesions because of the high affinity of bisphosphonate for hydroxyapatite, which is plentiful in bone but not in soft tissues21,22. Stable radiometal complex-conjugated bisphosphonate compounds have been designed as bone-seeking radiopharmaceuticals; they have been synthesized and evaluated for the diagnosis and therapy of bone metastases21–29. The available data show that bisphosphonate is an excellent carrier of radioisotopes to bone lesions. Our recent study has shown that L-aspartic acid peptides could also work as carriers of radioisotopes to bone lesions; L-aspartic acid peptides have high affinity for hydroxyapatite9,31. Thus, we assumed that D-aspartic acid peptides might be even better carriers. They should have a similar degree of affinity for hydroxyapatite but higher stability in vivo than the L-aspartic acid compounds.
In the hydroxyapatite-binding assay, $^{67}$Ga-DOTA-(D-Asp)$_n$ with a longer amino acid chain showed higher affinity for hydroxyapatite than the short-chain compounds. The binding patterns of $^{67}$Ga-DOTA-(D-Asp)$_n$ were almost the same as those of $^{67}$Ga-DOTA-(L-Asp)$_n$. A previous study reported that the dissociation constants and the maximal binding rates of Fmoc-peptide compounds for hydroxyapatite show no significant differences among Fmoc-(L-Asp)$_n$, Fmoc-(D-Asp)$_n$, and Fmoc-(L-Glu)$_n$ ($n = 2, 4, 6, 8, 10$). This is consistent with the results of hydroxyapatite binding assay in our study. We found that aspartic acid peptides had the same degree of affinity for hydroxyapatite regardless of their optical isomeric form. Moreover, there were no differences between the affinities of aspartic acid peptides and glutamic acid peptides for hydroxyapatite.

In vivo studies, it is known that the peptides that composed of D-amino acids are more stable than the L-amino acid peptides. A study examining the Fmoc compounds reported that, after a single i.v. administration, the plasma concentration of Fmoc-(L-Asp)$_n$ decreased more rapidly than the concentration of Fmoc-(D-Asp)$_n$. Degradation products did not appear in the plasma after the injection of Fmoc-(D-Asp)$_n$, but Fmoc-(L-Asp)$_4$ and Fmoc-(L-Asp)$_2$ were detected in plasma after the injection of Fmoc-(L-Asp)$_6$. Therefore, we had expected to

---

**Figure 1.** Chemical structures of (A) Ga-DOTA-Bn-SCN-HBP, (B) Ga-DOTA-(D-Asp)$_n$ ($n = 2, 5, 8, 11$, or $14$), (C) Ga-DOTA-(L-Glu)$_{14}$, and (D) Ga-DOTA-(D-Glu)$_{14}$. 
observe increased accumulation in bone after the injection of $^{67}$Ga-DOTA-(D-Asp)$_n$, caused by their superior in vivo stability. In urine analyses, $^{67}$Ga-DOTA-(L-Asp)$_{14}$ metabolized to more hydrophilic complexes, which should be $^{67}$Ga-DOTA conjugated with shorter aspartic acid peptides, because of the cleavage of an amide bond in the peptide. These compounds were diluted before the full-length compound during the RP-HPLC using an ODS column. This indicates that $^{67}$Ga-DOTA-(D-Asp)$_n$ is more stable than $^{67}$Ga-DOTA-(L-Asp)$_n$. Since $^{67}$Ga-DOTA conjugated with shorter aspartic acid peptides should show lower accumulation in bone than $^{67}$Ga-DOTA conjugated with longer aspartic acid peptides, we expected that $^{67}$Ga-DOTA-(D-Asp)$_n$, which has higher stability, would show higher accumulation in bone than $^{67}$Ga-DOTA-(L-Asp)$_n$. However, against our expectations, the accumulation of radioactivity in bone was comparable for $^{67}$Ga-DOTA-(L-Asp)$_n$ and $^{67}$Ga-DOTA-(D-Asp)$_n$. Not only $^{67}$Ga-DOTA-(D-Asp)$_n$ but also $^{67}$Ga-DOTA-(L-Asp)$_n$ immediately accumulated in bone or was excreted into urine via the kidneys with little degradation; both molecule types showed extremely rapid clearance from the blood. There was no difference between the biodistributions of $^{67}$Ga-DOTA-(L-Asp)$_n$ and $^{67}$Ga-DOTA-(D-Asp)$_n$.

To compare the biodistributions of $^{67}$Ga-DOTA-conjugated acidic amino acid peptides with the biodistributions of other typical bone-seeking compounds, biodistribution experiments of $^{99m}$Tc-MDP and $[^{18}$F]$NaF$ were
performed. $^{67}$Ga-DOTA-(D-Asp)$_5$, $^{67}$Ga-DOTA-(D-Asp)$_{14}$, $^{99m}$Tc-MDP, and $[^{18}$F$]$NaF showed excellent biodistribution as bone imaging agents, such as high bone accumulation and low radioactivity in non-target tissues. Among these agents, as $[^{18}$F$]$NaF showed the highest bone uptake, $[^{18}$F$]$NaF may have the most preferable biodistribution as a bone imaging agent. However, the bone/non-target tissue radioactivity ratios of $^{99m}$Tc-MDP and $^{67}$Ga-DOTA-(D-Asp)$_n$ ($n$ = 11 or 14) are sufficient for bone imaging, and $^{99m}$Tc and $^{68}$Ga have some convenient physical properties as radionuclides. Thus, $^{99m}$Tc-MDP and $^{68}$Ga-DOTA-(D-Asp)$_n$ ($n$ = 11 or 14) should be useful in a clinical context.

The $^{67}$Ga-DOTA-conjugated L-glutamic acid peptide, $^{67}$Ga-DOTA-(L-Glu)$_{14}$, and the $^{67}$Ga-DOTA-conjugated D-glutamic acid peptide, $^{67}$Ga-DOTA-(D-Glu)$_{14}$, also showed rapid clearance from the blood and high accumulation in bone, similarly to $^{67}$Ga-DOTA-(L-Asp)$_{14}$ and $^{67}$Ga-DOTA-(D-Asp)$_{14}$. Generally, radiometal-labeled peptides tend to show a high accumulation of radioactivity in the kidneys. It has been reported that the accumulation of radioactivity in the kidneys decreases the injection of $^{111}$In-labeled peptides is affected by molecular charges. As the renal brush border membrane is negatively charged, a repulsive force could arise between this membrane and negatively charged compounds. Such repulsive force could inhibit the reabsorption of these compounds into renal proximal tubular cells. The introduction of negative charges into radiometal-labeled peptides has also been studied to develop a method of decreasing the accumulation of radioactivity in the kidneys. The extremely low accumulation of radioactivity in the kidneys after the injection of $^{67}$Ga-DOTA-(L-Asp)$_{14}$ and

| Tissue          | Time after injection | 10 min | 60 min | 180 min |
|-----------------|----------------------|--------|--------|---------|
| Blood           | 2.81 (0.73)          | 0.27 (0.02) | 0.13 (0.07) |
| Liver           | 0.67 (0.13)          | 0.22 (0.11) | 0.14 (0.03) |
| Kidney          | 12.04 (4.05)         | 6.31 (3.64) | 1.45 (0.34) |
| Small-intestine | 0.55 (0.16)          | 0.23 (0.09) | 0.18 (0.19) |
| Large-intestine | 0.47 (0.13)          | 0.22 (0.27) | 0.22 (0.13) |
| Spleen          | 0.56 (0.12)          | 0.16 (0.05) | 0.11 (0.03) |
| Pancreas        | 0.72 (0.11)          | 0.25 (0.19) | 0.06 (0.00) |
| Lung            | 2.03 (0.34)          | 0.30 (0.11) | 0.09 (0.02) |
| Heart           | 1.03 (0.29)          | 0.12 (0.01) | 0.06 (0.01) |
| Stomach         | 0.32 (0.06)          | 0.10 (0.06) | 0.48 (0.89) |
| Bone (Femur)    | 6.78 (1.84)          | 5.01 (0.93) | 2.80 (0.58) |
| Muscle          | 0.68 (0.21)          | 0.13 (0.03) | 0.07 (0.03) |
| Brain           | 0.10 (0.05)          | 0.02 (0.01) | 0.01 (0.00) |
| F/B ratio$^c$   | 2.41 (0.22)          | 18.52 (2.59) | 25.42 (10.06) |

Table 2. Biodistribution of radioactivity after i.v. injection of $^{67}$Ga-DOTA-(D-Asp)$_5$ in mice. $^a$Expressed as % injected dose. Each value represents the mean (SD) for four animals. $^b$Expressed as % injected dose. $^c$Femur:blood ratio.

| Tissue          | Time after injection | 10 min | 60 min | 180 min |
|-----------------|----------------------|--------|--------|---------|
| Blood           | 1.94 (0.12)          | 0.33 (0.05) | 0.13 (0.05) |
| Liver           | 0.46 (0.06)          | 0.14 (0.02) | 0.11 (0.01) |
| Kidney          | 12.79 (9.18)         | 2.49 (2.15) | 1.23 (0.48) |
| Small-intestine | 0.39 (0.06)          | 0.13 (0.03) | 0.10 (0.06) |
| Large-intestine | 0.26 (0.02)          | 0.05 (0.00) | 0.08 (0.01) |
| Spleen          | 0.42 (0.02)          | 0.16 (0.05) | 0.09 (0.02) |
| Pancreas        | 0.57 (0.06)          | 0.11 (0.01) | 0.08 (0.02) |
| Lung            | 1.34 (0.10)          | 0.26 (0.03) | 0.10 (0.03) |
| Heart           | 0.63 (0.06)          | 0.14 (0.07) | 0.05 (0.02) |
| Stomach$^b$     | 0.34 (0.23)          | 0.04 (0.01) | 0.10 (0.13) |
| Bone (Femur)    | 9.86 (1.90)          | 11.63 (2.57) | 12.49 (2.61) |
| Muscle          | 0.57 (0.40)          | 0.15 (0.07) | 0.14 (0.16) |
| Brain           | 0.05 (0.00)          | 0.01 (0.01) | 0.01 (0.00) |
| F/B ratio$^c$   | 5.04 (0.77)          | 35.96 (13.10) | 122.09 (89.13) |

Table 3. Biodistribution of radioactivity after i.v. injection of $^{67}$Ga-DOTA-(D-Asp)$_8$ in mice. $^a$Expressed as % injected dose. Each value represents the mean (SD) for five animals. $^b$Expressed as % injected dose. $^c$Femur:blood ratio.
67Ga-DOTA-(D-Asp)14 may have been caused by their negative charges. We had expected that 67Ga-DOTA-(L-Glu)14 and 67Ga-DOTA-(D-Glu)14, being negatively charged like 67Ga-DOTA-(L-Asp)14 and 67Ga-DOTA-(D-Asp)14, would also cause low accumulation of radioactivity in the kidneys. However, contrary to our expectations, high accumulation and retention or slower clearance of radioactivity in the kidneys were observed after the injection of 67Ga-DOTA-(L-Glu)14 or 67Ga-DOTA-(D-Glu)14. The mechanism behind these phenomena are unclear, but we must conclude that the glutamic acid peptides are not appropriate as carriers to the bone in the nuclear medicine imaging because of their association with high radioactivity in the kidneys.

In this study, no differences in the biodistributions between L-aspartic acid [67Ga-DOTA-(L-Asp)n] and D-aspartic acid [67Ga-DOTA-(D-Asp)n] compounds were observed, presumably because of their extremely rapid blood clearance. Recently, we have proposed a new concept of using a bifunctional peptide containing an aspartic acid peptide linker as a carrier to bone metastases and an RGD peptide, which has high affinity for \( \alpha_v\beta_3 \) integrin, as a carrier to primary cancer31. In this compound, L-aspartic acid is used as a composite component of the aspartic acid peptide linker. A D-aspartic acid peptide linker may be effective in the new approach. Higher stability of the D-aspartic acid peptide linker should be effective for higher accumulation in target tissues because the blood clearance of bifunctional peptide does not occur as rapidly as that of 67Ga-DOTA-(D-Asp)n. Further studies are needed to examine the effectiveness of a D-aspartic acid peptide linker in the drug design concept.

### Table 4. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)14 in mice.

| Tissue              | 10 min | 60 min | 180 min |
|---------------------|--------|--------|---------|
| Blood               | 1.71 (0.21) | 0.14 (0.10) | 0.08 (0.04) |
| Liver               | 0.51 (0.08) | 0.20 (0.10) | 0.13 (0.06) |
| Kidney              | 12.83 (5.61) | 2.92 (3.25) | 1.00 (0.40) |
| Small-intestine     | 0.38 (0.07) | 0.07 (0.01) | 0.05 (0.01) |
| Large-intestine     | 0.28 (0.02) | 0.03 (0.01) | 0.11 (0.03) |
| Spleen              | 0.44 (0.08) | 0.13 (0.06) | 0.10 (0.02) |
| Pancreas            | 0.53 (0.07) | 0.09 (0.09) | 0.04 (0.01) |
| Lung                | 1.24 (0.18) | 0.08 (0.01) | 0.05 (0.01) |
| Heart               | 0.65 (0.11) | 0.04 (0.01) | 0.03 (0.01) |
| Stomach             | 0.18 (0.03) | 0.04 (0.02) | 0.02 (0.01) |
| Bone (Femur)        | 11.93 (0.55) | 15.26 (1.08) | 15.45 (1.65) |
| Muscle              | 0.58 (0.16) | 0.18 (0.10) | 0.06 (0.03) |
| Brain               | 0.05 (0.01) | 0.01 (0.01) | 0.02 (0.01) |
| F/B ratio           | 7.01 (0.56) | 147.10 (71.25) | 248.95 (170.64) |

### Table 5. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Asp)11 in mice.

| Tissue              | 10 min | 60 min | 180 min |
|---------------------|--------|--------|---------|
| Blood               | 2.46 (0.60) | 0.09 (0.04) | 0.03 (0.01) |
| Liver               | 0.51 (0.12) | 0.15 (0.04) | 0.05 (0.03) |
| Kidney              | 8.15 (3.86) | 1.21 (0.57) | 0.54 (0.12) |
| Small-intestine     | 0.55 (0.06) | 0.18 (0.04) | 0.12 (0.02) |
| Large-intestine     | 0.40 (0.06) | 0.10 (0.01) | 0.20 (0.01) |
| Spleen              | 0.48 (0.13) | 0.12 (0.03) | 0.12 (0.04) |
| Pancreas            | 0.88 (0.07) | 0.27 (0.04) | 0.14 (0.06) |
| Lung                | 1.75 (0.47) | 0.28 (0.09) | 0.03 (0.01) |
| Heart               | 0.94 (0.16) | 0.18 (0.04) | 0.11 (0.03) |
| Stomach             | 0.28 (0.08) | 0.07 (0.01) | 0.06 (0.01) |
| Bone (Femur)        | 11.90 (2.99) | 13.03 (0.90) | 14.78 (2.34) |
| Muscle              | 0.77 (0.15) | 0.16 (0.03) | 0.16 (0.11) |
| Brain               | 0.06 (0.01) | 0.01 (0.01) | 0.01 (0.00) |
| F/B ratio           | 4.90 (0.70) | 180.99 (91.94) | 526.37 (130.49) |
Methods

Materials. Electrospray ionization mass (ESI-MS) analyses were performed with a LCQ (Thermo Fisher Scientific, Waltham, MA, USA). Matrix assisted laser desorption/ionization-time of flight mass (MALDI-TOF-MS) analyses were performed with ABI 4800 plus (AB SCIEX, Foster, CA, USA). [67Ga]GaCl₃ was supplied by Nihon Medi-Physics Co., Ltd. (Tokyo, Japan). [18F]NaF was prepared in Fukui University and transported to Kanazawa University. [99mTc]Pertechnetate (99mTcO₄⁻) was eluted in saline solution from generators (Nihon Medi-Physics Co., Ltd). 99mTc-MDP was prepared by the addition of 99mTcO₄⁻ solution into the mixture of MDP (Wako Pure Chemical Industries, Ltd., Osaka, Japan), tin(II) chloride, and ascorbic acid solution. 1,4,7,10-Tetraazacyclododecane-1,4,7-tris(t-butyl acetate) (DOTA-tris) was purchased from Macrocyclics (Dallas, TX, USA). 9-Fluorenylmethoxycarbonyl (Fmoc)-D-Asp(OtBu)-Wang resin, Fmoc-D-Asp(OtBu), and Fmoc-L-Glu(OtBu) were purchased from Merck KGaA (Darmstadt, Germany). Fmoc-L-Glu(OtBu)-Wang resin and 2-chlorotrityl chloride resin were purchased from Watanabe chemical Industries, LTD. (Hiroshima, Japan). Fmoc-D-Glu(OtBu) was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Other reagents were of reagent grade and used as received.

Synthesis of DOTA-(D-Asp)ₙ (n = 2, 5, 8, 11, or 14). The protected peptidyl resin was manually constructed by an Fmoc-based solid-phase methodology using a method described previously²⁹. After

| Tissue          | Time after injection |
|-----------------|----------------------|
|                 | 10 min | 60 min | 180 min |
| Blood           | 1.85 (0.47) | 0.12 (0.04) | 0.05 (0.02) |
| Liver           | 0.47 (0.16) | 0.13 (0.03) | 0.14 (0.04) |
| Kidney          | 22.06 (4.67) | 26.41 (6.53) | 25.14 (3.75) |
| Small-intestine | 0.50 (0.14) | 0.13 (0.05) | 0.15 (0.09) |
| Large-intestine | 0.37 (0.13) | 0.07 (0.01) | 0.23 (0.15) |
| Spleen          | 0.44 (0.12) | 0.10 (0.03) | 0.11 (0.06) |
| Pancreas        | 0.59 (0.15) | 0.13 (0.02) | 0.08 (0.02) |
| Lung            | 1.57 (0.42) | 0.13 (0.03) | 0.06 (0.02) |
| Heart           | 0.67 (0.22) | 0.10 (0.02) | 0.06 (0.01) |
| Stomach³        | 0.22 (0.03) | 0.07 (0.05) | 0.07 (0.07) |
| Bone (Femur)    | 9.81 (2.35) | 11.07 (1.66) | 10.90 (1.17) |
| Muscle          | 0.63 (0.12) | 0.10 (0.05) | 0.30 (0.47) |
| Brain           | 0.05 (0.01) | 0.01 (0.00) | 0.03 (0.01) |
| F/B ratio²     | 5.41 (0.93) | 97.50 (26.27) | 239.85 (89.95) |

Table 6. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(L-Glu)₁₄ in mice. *Expressed as % injected dose. Each value represents the mean (SD) for five animals. †Expressed as % injected dose. ‡Femur:blood ratio.

| Tissue          | Time after injection |
|-----------------|----------------------|
|                 | 10 min | 60 min | 180 min |
| Blood           | 2.09 (0.35) | 0.10 (0.02) | 0.01 (0.01) |
| Liver           | 0.46 (0.07) | 0.12 (0.03) | 0.08 (0.02) |
| Kidney          | 13.43 (3.15) | 10.61 (5.38) | 6.59 (1.74) |
| Small-intestine | 0.37 (0.03) | 0.22 (0.15) | 0.15 (0.05) |
| Large-intestine | 0.42 (0.05) | 0.18 (0.17) | 0.25 (0.12) |
| Spleen          | 0.37 (0.06) | 0.06 (0.02) | 0.03 (0.02) |
| Pancreas        | 0.68 (0.26) | 0.13 (0.05) | 0.06 (0.02) |
| Lung            | 1.65 (0.44) | 0.13 (0.02) | 0.04 (0.01) |
| Heart           | 0.79 (0.13) | 0.08 (0.02) | 0.05 (0.02) |
| Stomach³        | 0.29 (0.06) | 0.19 (0.11) | 0.29 (0.23) |
| Bone (Femur)    | 10.98 (0.49) | 11.78 (1.21) | 12.20 (2.41) |
| Muscle          | 0.78 (0.31) | 0.19 (0.22) | 0.02 (0.01) |
| Brain           | 0.05 (0.01) | 0.01 (0.00) | 0.01 (0.00) |
| F/B ratio²     | 5.39 (1.05) | 129.55 (40.09) | 1179.73 (699.19) |

Table 7. Biodistribution of radioactivity after i.v. injection of 67Ga-DOTA-(D-Glu)₁₄ in mice. *Expressed as % injected dose. Each value represents the mean (SD) for four animals. †Expressed as % injected dose. ‡Femur:blood ratio.
the construction of the peptide chain on the resin, the Fmoc protecting group was removed using 20% piperidine in dimethylformamide (DMF), and a mixture containing two equivalents of DOTA-tris, 1,3-diisopropylcarbodiimide (DIPCDI), and 1-hydroxybenzotriazole hydrate (HOBt) in dimethylformamide (DMF) was added and allowed to react for 2 h. For the cleavage of peptides from the resin and deprotection, 0.5 mL of thioanisole and 5 mL of trifluoroacetic acid (TFA) were added to the completely protected peptide resin at 0 °C. After stirring at room temperature for 2 h, the resin was removed by filtration, and ether was added to the filtrate at 0 °C to precipitate crude peptide. The crude products were purified by reversed-phase (RP)-HPLC using a Hydrosphere 5C18 column (10 × 150 mm; YMC, Kyoto, Japan) at a flow rate of 4 mL/min with an iso-
cratic mobile phase of water containing 0.1% TFA [in the case of DOTA-(D-Asp)2] or using a Cosmosil 5C 18-AR 300 column (10 × 150 mm; Nacalai Tesque, Kyoto, Japan) at a flow rate of 4 mL/min with a gradient mobile
phase from water containing 0.1% TFA to 20% methanol in water containing 0.1% TFA for 20 min [in the case of DOTA-(D-Asp)n (n = 5, 8, 11, or 14)]. UV Chromatograms (220 nm) were obtained. The fraction containing
DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14) was determined by mass spectrometry and collected. The solvent removal
from the fraction was performed by freeze-drying to provide DOTA-(D-Asp)n as white powder.

| Tissue         | Time after injection | 10 min | 60 min | 180 min |
|----------------|----------------------|--------|--------|---------|
| Blood          | 1.78 (0.23)          | 0.11 (0.04) | 0.02 (0.00) |
| Liver          | 1.34 (0.17)          | 0.09 (0.02) | 0.02 (0.00) |
| Kidney         | 5.23 (2.31)          | 1.13 (0.89) | 0.15 (0.08) |
| Small-intestine| 1.31 (0.22)          | 0.68 (0.10) | 0.06 (0.02) |
| Large-intestine| 0.95 (0.22)          | 1.21 (0.27) | 1.39 (0.19) |
| Spleen         | 1.10 (0.15)          | 0.08 (0.02) | 0.02 (0.00) |
| Pancreas       | 0.87 (0.15)          | 0.08 (0.08) | 0.02 (0.03) |
| Lung           | 1.44 (0.19)          | 0.10 (0.03) | 0.03 (0.01) |
| Heart          | 1.84 (0.41)          | 0.15 (0.05) | 0.02 (0.01) |
| Stomach       | 0.36 (0.04)          | 0.06 (0.02) | 0.13 (0.14) |
| Bone (Femur)   | 27.69 (3.15)         | 39.96 (2.52) | 43.91 (2.64) |
| Muscle         | 0.83 (0.13)          | 0.07 (0.04) | 0.01 (0.01) |
| Brain          | 0.10 (0.02)          | 0.36 (0.52) | 0.05 (0.02) |
| F/B ratio     | 15.59 (1.01)         | 381.63 (84.17) | 1983.88 (256.88) |

Table 8. Biodistribution of radioactivity after i.v. injection of [18F]NaF in mice#. aExpressed as % injected dose. Each value represents the mean (SD) for four animals. bExpressed as % injected dose. cFemur:blood ratio.

| Tissue         | Time after injection | 10 min | 60 min | 180 min |
|----------------|----------------------|--------|--------|---------|
| Blood          | 2.43 (0.10)          | 0.23 (0.04) | 0.05 (0.01) |
| Liver          | 0.61 (0.02)          | 0.27 (0.05) | 0.16 (0.04) |
| Kidney         | 10.44 (1.56)         | 2.03 (0.50) | 1.22 (0.36) |
| Small-intestine| 0.69 (0.15)          | 1.55 (1.68) | 0.26 (0.08) |
| Large-intestine| 0.61 (0.20)          | 0.14 (0.04) | 0.23 (0.07) |
| Spleen         | 0.54 (0.07)          | 0.14 (0.02) | 0.07 (0.01) |
| Pancreas       | 0.77 (0.10)          | 0.13 (0.02) | 0.07 (0.01) |
| Lung           | 1.80 (0.16)          | 0.30 (0.03) | 0.10 (0.02) |
| Heart          | 0.94 (0.05)          | 0.16 (0.02) | 0.07 (0.02) |
| Stomach       | 0.63 (0.14)          | 0.70 (0.37) | 0.29 (0.07) |
| Bone (Femur)   | 20.76 (1.51)         | 27.92 (3.25) | 29.03 (2.12) |
| Muscle         | 0.57 (0.09)          | 0.13 (0.04) | 0.06 (0.01) |
| Brain          | 0.06 (0.01)          | 0.02 (0.00) | 0.01 (0.00) |
| F/B ratio     | 8.54 (0.57)          | 120.87 (9.30) | 546.64 (91.83) |

Table 9. Biodistribution of radioactivity after i.v. injection of 99mTc-MDP in mice#. aExpressed as % injected dose. Each value represents the mean (SD) for four animals. bExpressed as % injected dose. cFemur:blood ratio.
Synthesis of DOTA-(L-Glu)$_{14}$. A resin-binding protected peptide was constructed by the same procedure as mentioned above using Fmoc-L-Glu(OtBu)-Wang resin, Fmoc-L-Glu(OtBu), and tris-DOTA. For the cleavage of peptides from the resin and the deprotection, 0.5 mL of thioanisole and 5 mL of TFA were added to the fully protected peptide resin at 0 °C. After stirring at room temperature for 2 h, the crude product was purified by RP-HPLC at a flow rate of 4 mL/min with a gradient mobile phase from water containing 0.1% TFA to 20% methanol in water containing 0.1% TFA for 20 min. The solvent removal from the fraction was performed by freeze-drying to provide DOTA-(L-Glu)$_{14}$ and as white powder.

DOTA-(L-Glu)$_{14}$ MS (ESI): m/z 2212 (M + H)$^+$, Yield: 14.6%

Synthesis of DOTA-(D-Glu)$_{14}$. Fmoc-D-Glu(OtBu) (4 molar equivalents to resin) was dissolved in dichloromethane. 2-Chlorotriyl chloride resin and N,N-diisopropylethylamine (DIEA, 3.5 equiv.) were added. The reaction mixture was rotated for 1 h, and 1 mL of methanol was added to react further for 30 min at room temperature. Construction, cleavage, deprotection, and purification of the peptide were performed by the same procedure as mentioned above. DOTA-(D-Glu)$_{14}$ was obtained as white powder.

DOTA-(D-Glu)$_{14}$ MS (ESI): m/z 2212 (M + H)$^+$, Yield: 2.1%

Preparation of Ga-DOTA-(D-Asp)$_n$ (n = 2, 5, 8, 11, or 14), Ga-DOTA-(L-Glu)$_{14}$, and Ga-DOTA-(D-Glu)$_{14}$. Ga-DOTA-(D-Asp)$_n$ (n = 2, 5, 8, 11, or 14), Ga-DOTA-(L-Glu)$_{14}$, and Ga-DOTA-(D-Glu)$_{14}$ were synthesized using a method described previously.

Ga-DOTA-(D-Asp)$_n$ MS (ESI): m/z 701 (M)$^+$
Ga-DOTA-(D-Asp)$_n$ MS (ESI): m/z 1046 (M)$^+$
Ga-DOTA-(D-Asp)$_n$ MS (ESI): m/z 1391 (M)$^+$
Ga-DOTA-(D-Asp)$_{14}$ MS (ESI): m/z 1736 (M)$^+$
Ga-DOTA-(D-Asp)$_{14}$ MS (MALDI): m/z 2081 (M)$^+$
Ga-DOTA-(L-Glu)$_{14}$ MS (ESI): m/z 2278 (M)$^+$
Ga-DOTA-(D-Glu)$_{14}$ MS (ESI): m/z 2278 (M)$^+$

Preparation of $^{67}$Ga-DOTA-(D-Asp)$_n$ (n = 2, 5, 8, 11, or 14), $^{67}$Ga-DOTA-(L-Glu)$_{14}$, and $^{67}$Ga-DOTA-(D-Glu)$_{14}$. Approximately 50 μg of DOTA-(D-Asp)$_n$ (n = 2, 5, 8, 11, or 14), DOTA-(L-Glu)$_{14}$ or DOTA-(D-Glu)$_{14}$ was dissolved in 75 μL of 0.2 M ammonium acetate buffer (pH 5.0), and 25 μL of $^{67}$GaCl$_3$ solution (1.85 MBq) in 0.01 M HCl was added and allowed to react at 80 °C for 8 min. $^{67}$Ga-labeled peptides were purified by RP-HPLC performed using a Hydrosphere 5C18 column (4.6 × 250 mm; YMC) at a flow rate of 1 mL/min with an isocratic mobile phase of water containing 0.1% TFA [in the case of $^{67}$Ga-DOTA-(D-Asp)$_n$] or using a Cosmosil 5C$_{18}$-AR 300 column (4.6 × 150 mm) at a flow rate of 1 mL/min with a gradient mobile phase from water containing 0.1% TFA to 20% methanol in water containing 0.1% TFA for 20 min [in the case of $^{67}$Ga-DOTA-(D-Glu)$_{14}$].

Preparation of $^{[18F]}$NaF. No-carrier-added $^{[18F]}$fluoride was produced via the $^{18}$O(p,n)$^{18}$F reaction from >98% enriched $^{18}$O(water (Taiyo Nippon Sanso Corporation, Tokyo, Japan) on an RDS eclipse RD/HP medical cyclotron (Siemens, Knoxville, TN, USA). $^{[18F]}$NaF was prepared by eluting $^{[18F]}$fluoride trapped on an anion exchange column (QMA Plus Light; Waters Corporation, Milford, MA, USA) with saline after washing the anion exchange column with water.

Hydroxyapatite-binding assays. Hydroxyapatite-binding assays were performed in accordance with previously described procedures. In brief, hydroxyapatite beads (Bio-Gel, Bio-Rad, Hercules, CA, USA) were suspended in Tris/HCl-buffered saline (50 mM, pH 7.4) at 2.5 mg/mL, 10 mg/mL, and 25 mg/mL. For the solutions of $^{67}$Ga-DOTA-(D-Asp)$_n$ (n = 2, 5, 8, 11, or 14), $^{67}$Ga-DOTA-(L-Glu)$_{14}$, or $^{67}$Ga-DOTA-(D-Glu)$_{14}$, ligand concentrations were adjusted to 19.5 μM by adding DOTA-(D-Asp)$_n$, DOTA-(L-Glu)$_{14}$, or DOTA-(D-Glu)$_{14}$. Two hundred microliters of each of $^{67}$Ga-DOTA-(D-Asp)$_n$, $^{67}$Ga-DOTA-(L-Glu)$_{14}$, or $^{67}$Ga-DOTA-(D-Glu)$_{14}$ solution was added to 200 μL of the hydroxyapatite suspension, and samples were gently shaken for 1 h at room temperature. After centrifugation at 10,000 × g for 5 min, a part of the radioactivity in the supernatants was measured using a gamma counter (AccuFLEX γ ARC-7010, Hitachi, Ltd., Tokyo, Japan). Control experiments were performed according to the same procedure without hydroxyapatite beads, which showed < 0.1% adsorption of radioactivity to vials. The ratios of binding were determined as follows:

Hydroxyapatite binding (%) = (1 − [sample supernatant radioactivity]/[control supernatant radioactivity]) × 100

Biodistribution experiments. Experiments with animals were conducted in strict accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University. The animal experimental protocols were approved by the Committee on Animal Experimentation of Kanazawa University (Permit Number: AP-132633). Biodistribution experiments were performed after intravenous administration of each diluted tracer solution (37–700 kBq/100 μL) to 6-week-old male ddY mice (27–32 g, Japan SLC, Inc., Hamamatsu, Japan).Four or five mice at each time point after the administration of each compound were sacrificed by decapitation at 10, 60, and 180 min post-injection. Tissues of interest were taken and weighed. Complete left femurs were isolated as representative bone samples. Radioactivity was determined using gamma counters (AccuFLEX γ ARC-8001 in the case of $^{18}$F, Hitachi, Ltd.), and background counts and physical decay were corrected during counting.
Urine Analyses. \(^{67}\text{Ga-DOTA-(L-Asp)}_{14}\) was prepared according to a method described previously. \(^{67}\text{Ga-DOTA-(L-Asp)}_{14}\) or \(^{67}\text{Ga-DOTA-(D-Asp)}_{14}\) solution (370 kBq / 200 μL) was intravenously injected to 6-week-old male ddY mice. At 1 h post-injection, mice were sacrificed and their urine samples were taken from the bladders. After ultrafiltration (Microcon-30, Merck KGaA), the filtrate samples were analyzed by RP-HPLC at a flow rate of 1 ml/min with a gradient mobile phase from water containing 0.1% TFA to 20% methanol in water containing 0.1% TFA for 20 min.

References
1. Mari, C., Catafau, A. & Carrio, I. Bone scintigraphy and metabolic disorders. J Nucl Med 43, 259–267 (1999).
2. Love, C., Din, A. S., Tomas, M. B., Kalapparambath, T. P. & Palestro, C. J. Radionuclide bone imaging: an illustrative review. Radiographics 23, 341–358 (2003).
3. Ogawa, K. & Saji, H. Advances in drug design of radiometa-based imaging agents for bone disorders. Int J Mol Imaging 2011, 537667 (2011).
4. Ogawa, K. & Mukai, T. Targeted imaging and therapy for bone metastases: control of pharmacokinetics of bone-targeted radiopharmaceuticals. J Drug Deliv Sci Tec 19, 171–176 (2009).
5. Ogawa, K. & Ishizaki, A. Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases. Nucl Med Biol 38, 631–636 (2011).
6. Fellner, M. et al. PET/CT imaging of osteoblastic bone metastases with \(^{68}\text{Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 37}, 834 (2010).
7. Wu, Z. et al. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent. Nucl Med Biol 38, 631–636 (2011).
8. Fellner, M. et al. Development of novel radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent. Nucl Med Biol 38, 631–636 (2011).
9. Wu, Z. et al. New \(^{68}\text{Ga-PenA bisphosphonates as potential bone imaging agents. Nucl Med Biol 43}, 360–371 (2016).
10. Uehara, T. et al. Assessment of \(^{99m}\text{Tc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, }^{18}\text{F-fluoride PET, and }^{18}\text{F-fluoride PET/CT. J Nucl Med 47}, 287–297 (2006).
11. Even-Sapir, E. et al. The detection of bone metastases in patients with high-risk prostate cancer: \(^{90}\text{Y-MAG3-conjugated bisphosphonate: a potential PET radiotracer for bone imaging. Contrast Media Mol Imaging 10}, 122–134 (2015).
12. Kasugai, S., Fujisawa, R., Waki, Y., Miyamoto, K. & Ohya, K. Selective drug delivery system to bone: small peptide (Asp) derivative. Bioconjug Chem 22, 3496–3506 (2011).
13. Cole, L. E., Vargo-Gogola, T. & Roeder, R. K. Targeted delivery to bone and mineral deposits using oligo-aspartic acid peptides as carriers. PLoS One 8, e48335 (2013).
14. Koyama, K. et al. Development of novel radiogallium-labeled bone imaging agents using olsog-aspartic acid peptides as carriers. J Bone Miner Res 15, 936–943 (2000).
15. Hongo, S. Y., Oh, J. E. & Lee, K. H. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58, 1775–1780 (1999).
16. Yewle, J. N., Puleo, D. A. & Bachas, L. G. Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone. Bioconjug Chem 22, 2496–2506 (2011).
17. Ogawa, K. et al. Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Comp Radiopharm 47, 753–761 (2004).
18. Ogawa, K. et al. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16, 751–757 (2005).
19. Ogawa, K. et al. Development of novel radiogallium-labeled bone imaging agents using olsog-aspartic acid peptides as carriers. J Nucl Med Biol 33, 523–527 (2006).
20. Ogawa, K. et al. Therapeutic effects of a \(^{188}\text{Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med 48}, 122–127 (2007).
21. Ogawa, K. et al. Development of \(^{186}\text{Re-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 47}, 2042–2047 (2006).
22. Ogawa, K. et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target 9, 111–121 (2001).
23. Akizawa, H. et al. Effect of molecular charges on renal uptake of \(^{111}\text{In-DTPA-conjugated peptides. Nucl Med Biol 28}, 761–768 (2001).
24. Akizawa, H. et al. Effect of carboxyl-group of D-glutamic acid or gamma-carboxy-D-glutamic acid as N-terminal amino acid of \(^{111}\text{In-diethyltartraminopteridine-acetate on accumulation of radioactivity in kidney. Biol Pharm Bull 30}, 2226–2228 (2007).
25. Oshima, N. et al. Design, synthesis and biological evaluation of negatively charged \(^{111}\text{In-DTPA-octreotide derivatives. Bioorg Med Chem 22}, 1377–1382 (2014).
Acknowledgements
This work was supported in part by Sagawa Foundation for Promotion of Cancer Research, Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI Grant Number 15K09948) from Japan Society for the Promotion of Science, Terumo Life Science Foundation, and Mochida Memorial Foundation for Medical and Pharmaceutical Research.

Author Contributions
K.O. and K.T. designed the study. K.O., A.I., and K.T. carried out the experiments. A.M. and Y.K. prepared \[^{18}F\] NaF. A.I. and K.T. analyzed the data. K.O. wrote the paper. K.O., A.I., K.T., Y.K., A.M., T.K., Y.K., K.S., and A.O. discussed the results and reviewed the manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017